Back
Repligen 10K Form
Buy
56
RGEN
Repligen
Last Price:
146.39
Seasonality Move:
9.8%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-01 | 10Q | RGEN/Repligen Quarterly |
| 2023-10-31 | 10Q | RGEN/Repligen Quarterly |
| 2023-08-02 | 10Q | RGEN/Repligen Quarterly |
| 2023-05-02 | 10Q | RGEN/Repligen Quarterly |
| 2022-11-01 | 10Q | RGEN/Repligen Quarterly |
| 2022-08-02 | 10Q | RGEN/Repligen Quarterly |
Receive RGEN News And Ratings
See the #1 stock for the next 7 days that we like better than RGEN
RGEN Financial Statistics
Sales & Book Value
| Annual Sales: | $638.76M |
|---|---|
| Cash Flow: | $34.79M |
| Price / Cash Flow: | 69.06 |
| Annual Sales: | $35.53 |
| Price / Book: | 4.12 |
Profitability
| EPS (TTM): | -0.04000 |
|---|---|
| Net Income (TTM): | $-1.9M |
| Gross Margin: | $284.84M |
| Return on Equity: | -0.1% |
| Return on Assets: | -0.07% |
Repligen Earnings Forecast
Key Repligen Financial Ratios
- The Gross Profit Margin over the past 39 years for RGEN is 44.59%.
- The Selling, General & Administrative Expenses for RGEN have been equal to 34.15% of Gross Profit Margin.
- The Research & Development expenses have been 6.69% of Revenue.
- The Interest Expense is 4.69% of Operating Income.
- The Net Earning history of RGEN is 6.51% of Total Revenues.
- Per Share Earnings over the last 39 years have been positive in 18 years.
Repligen Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Life Sciences Tools & Services |
| Sector: | Health Care |
| Current Symbol: | RGEN |
| CUSIP: | 759916 |
| Website: | repligen.com |
Debt
| Debt-to-Equity Ratio: | 0.3 |
|---|---|
| Current Ratio: | 6.65 |
| Quick Ratio: | 5.35 |
Price-to-Earnings
| Trailing P/E Ratio: | 197.23 |
|---|---|
| Forward P/E Ratio: | 78.23 |